Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 11 to 20 of 330

TitleReference numberPublishedLast updated
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitableTA1097
Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancerTA1092
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatmentsTA1091
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)TA1089
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrenceTA1086
Fruquintinib for previously treated metastatic colorectal cancerTA1079
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (terminated appraisal)TA1076
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1071
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)TA1072

Results per page

  1. 10
  2. 25
  3. 50
  4. All